Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
B 178.49 0.34% 0.61
ABBV closed up 0.34 percent on Monday, March 18, 2024, on 1.57 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
18 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Spinning Top Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 0.34%
Volume Surge Other 0.34%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
Rose Above 20 DMA about 13 hours ago
20 DMA Support about 13 hours ago
Reversed from Up about 14 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AbbVie Inc. Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Pharmaceutical Plastic Autoimmune Disease Infection Psoriasis Regenerative Medicine Ulcerative Colitis Anemia Depressive Disorder Hepatitis C Atopic Dermatitis Crohn's Disease Hematological Malignancies Hepatitis C Virus Constipation Irritable Bowel Syndrome Migraine Blood Cancers Immunosuppressants Skincare Products Psoriatic Arthritis Treatment Of Migraine Adalimumab Combination Drugs Endometriosis Eye Care Products Genotype Uterine Fibroid Advanced Prostate Cancer Chronic Idiopathic Constipation Hypothyroidism Ocular Hypertension Severe Plaque Psoriasis Spondylitis

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 182.89
52 Week Low 127.0269
Average Volume 5,460,761
200-Day Moving Average 149.93
50-Day Moving Average 171.83
20-Day Moving Average 178.56
10-Day Moving Average 179.76
Average True Range 3.04
RSI (14) 55.36
ADX 43.75
+DI 18.43
-DI 11.71
Chandelier Exit (Long, 3 ATRs) 173.76
Chandelier Exit (Short, 3 ATRs) 182.27
Upper Bollinger Bands 181.99
Lower Bollinger Band 175.12
Percent B (%b) 0.49
BandWidth 3.85
MACD Line 2.26
MACD Signal Line 2.86
MACD Histogram -0.603
Fundamentals Value
Market Cap 315.13 Billion
Num Shares 1.77 Billion
EPS 2.72
Price-to-Earnings (P/E) Ratio 65.62
Price-to-Sales 5.68
Price-to-Book 25.41
PEG Ratio 1.62
Dividend 5.99
Dividend Yield 3.36%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 181.96
Resistance 3 (R3) 182.04 180.96 181.38
Resistance 2 (R2) 180.96 180.08 180.92 181.19
Resistance 1 (R1) 179.73 179.53 179.19 179.65 181.00
Pivot Point 178.65 178.65 178.38 178.61 178.65
Support 1 (S1) 177.41 177.76 176.87 177.33 175.98
Support 2 (S2) 176.33 177.21 176.29 175.79
Support 3 (S3) 175.10 176.33 175.60
Support 4 (S4) 175.02